Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Investor World Review.
Press releases published on May 12, 2025

Stereotaxis Reports 2025 First Quarter Financial Results
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. “We’ve …

HighPeak Energy, Inc. Announces First Quarter 2025 Financial and Operating Results
FORT WORTH, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter ended March 31, 2025, provided an updated 2025 development outlook and …

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, …

Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from …

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) …

Assertio Reports First Quarter 2025 Financial Results
First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook Provides Update on Long-Term Business Strategy Designed to Create Sustainable Near-Term Growth and Increased Long-Term Value LAKE FOREST, Ill., May 12, 2025 (GLOBE NEWSWIRE) …

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 …

CompoSecure Reports First Quarter 2025 Financial Results
Operating results in line with expectations Reiterating previously issued full-year 2025 guidance Completed spin-off of Resolute Holdings Management, Inc. (Nasdaq: RHLD) Accounting standards related to the spin-off require the Company to report results …

Resolute Holdings Reports First Quarter 2025 Results
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Resolute Holdings Management, Inc. (“Resolute Holdings”) (Nasdaq: RHLD), an operating management company responsible for providing management services to CompoSecure Holdings, L.L.C. (“CompoSecure Holdings”), a …

Priority Income Fund Announces Redemption of its 6.625% Series F Term Preferred Stock Due 2027
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Priority Income Fund, Inc. (“Priority Income Fund” or the “Fund”) announced today that it will redeem all outstanding shares of its 6.625% Series F Term Preferred Stock Due 2027 (CUSIP: 74274W 822; NYSE: PRIF PRF) …

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R…

Plug Reports First Quarter 2025 Financial Results
SLINGERLANDS, N.Y., May 12, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions, today announced its financial results and operational milestones for the first quarter ended March 31, 2025. The …

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and vacated-in-part the Patent Trial and …

CPS Announces First Quarter 2025 Earnings
Revenues of $106.9 million compared to $91.7 million in the prior year period Net income of $4.7 million, or $0.19 per diluted share Total portfolio balance of $3.615 billion, highest in company history New contract purchases of $451.2 million LAS VEGAS, …

MYR Group Inc. to Attend 2025 Wells Fargo Industrials & Materials Conference in June
THORNTON, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial and industrial construction markets in the United …

Main Street Financial Services Corp. Annual Meeting Voting Results
WOOSTER, Ohio, May 12, 2025 (GLOBE NEWSWIRE) -- On May 8, 2025, Main Street Financial Services Corp. (OTCQX: MSWV) (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The inspector of elections delivered its final report of …

CAR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Avis Budget Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

NSSC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that NAPCO Security Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …

Quest Resource Holding Corporation Reports First Quarter 2025 Financial Results
Operating performance in line with expectations Sale of non-core business for $5 million used to pay down debt Savings of $3 million annually through elimination of costs associated with sold non-core business, and reduction of headcount Amended agreements …

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results
Preliminary net revenue increased 73% to $72.5 million for Q1 2025, compared to $41.9 million in Q1 2024 Achieved preliminary GAAP net income of $4.5 million, or $0.27 per share Reported preliminary Q1 2025 Adjusted EBITDA of $7.8 million Quarter-end cash …